Article

Cancer patients facing delays in receiving paclitaxel

The FDA released information today regarding manufacturing delays and an increase in demand for paclitaxel injection, a generic drug used for many different types of cancers. (You can read the full brief at FDA Drug Shortages.)This marks only the latest cancer drug shortage. Problems with paclitaxel availability were first announced in May (more information can be found in Drug Shortages Leave Cancer Patients at Risk via Medpage Today).The New York Times published an excellent opinion piece this past weekend by Ezekiel J. Emanuel (Shortchanging Cancer Patients) that explained how and why so many of these drug shortages are happening -- all of which are generic and inexpensive drugs. We'll be reporting more on this topic in an upcoming CURE issue, so stay tuned. In the meantime, let us know if and how you've been affected by the recent drug shortages.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Related Content